218916-64-4

Usage

Uses

Used in Biochemistry and Organic Chemistry Research:
Boc-Glu-OH is employed as a reagent in the synthesis of peptides and proteins, facilitating the study of biological processes and pathways. Its versatile structure and compatibility with a range of solvents and reactions make it a popular choice for researchers and scientists.
Used in Pharmaceutical Development:
In the pharmaceutical industry, Boc-Glu-OH is utilized in the development of new drugs and therapeutic agents. Its unique structure allows for the creation of novel compounds with potential applications in treating various diseases and conditions.
Used in Chemical Synthesis:
Boc-Glu-OH is also used in the chemical synthesis industry for the production of various compounds and materials. Its stability and reactivity make it a valuable component in the synthesis of complex organic molecules.
Used in Analytical Chemistry:
In analytical chemistry, Boc-Glu-OH serves as a reference compound for the development and validation of analytical methods and techniques. Its well-defined structure and properties enable accurate measurements and assessments in various analytical applications.

InChI:C

SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name	2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid

1.2 Other means of identification

Product number	-
Other names	Boc-3-amino-2-hydroxypropionic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses	For industry use only.
Uses advised against	no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number	-
Service hours	Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:218916-64-4 SDS

Upstream product

• 632-12-2 (RS)-isoserine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 458531-74-3 {2-Hydroxy-2-[(S)-2-methyl-1-((S)-1-methylcarbamoyl-2-phenyl-ethylcarbamoyl)-propylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 458531-70-9 {2-Hydroxy-2-[(S)-1-((S)-2-methyl-1-methylcarbamoyl-propylcarbamoyl)-2-phenyl-ethylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 458531-72-1 {2-Hydroxy-2-[(S)-1-((S)-3-methyl-1-methylcarbamoyl-butylcarbamoyl)-2-phenyl-ethylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 458531-69-6 {2-Hydroxy-2-[(S)-3-methyl-1-((S)-1-methylcarbamoyl-2-phenyl-ethylcarbamoyl)-butylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 458531-66-3 (2-Hydroxy-2-{(S)-1-[(S)-2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethylcarbamoyl]-3-methyl-butylcarbamoyl}-ethyl)-carbamic acid tert-butyl ester 
• 458531-71-0 {2-Hydroxy-2-[(S)-1-((S)-1-methylcarbamoyl-2-phenyl-ethylcarbamoyl)-2-phenyl-ethylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 113525-87-4 methyl 3-((tert-butoxycarbonyl)amino)-2-hydroxypropanoate 
• 1350881-23-0 tert-butyl {2-(benzyloxy)-2-[3-(4-chlorophenyl)-1-(pyrimidin-2-yl)-1H-pyrazol-5-yl]ethyl}carbamate 
• 1350881-22-9 tert-butyl {2-(benzyloxy)-2-[3-(4-chloropheny)-1H-pyrazol-5-yl]ethyl}carbamate 
• 1350881-21-8 tert-butyl [2-(benzyloxy)-5-(4-chlorophenyI)-3-oxopent-4-yn-1-yl]carbamate 
• 1350881-20-7 tert-butyl {2-(benzyloxy)-3-[methoxy(methyl)amino]-3-oxopropyl}carbamate 
• 1020253-58-0 2-(benzyloxy)-3-[(tert-butoxycarbonyl)amino]propanoic acid 
• 1350881-19-4 benzyl 2-(benzyloxy)-3-[(tert-butoxycarbonyl)amino]propanoate 
• 252329-85-4 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(3-t-butoxycarbonylamino-2(R,S)-hydroxy-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AND THEIR USE

The present invention provides compounds of the general formula (I) or a pharmaceutically acceptable prodrugs, salts and/or solvates thereof, wherein LHS is selected from the group consisting of LHSa and LHSb And wherein, the asterisk (*) marks the point of attachment; These compounds exhibit antibacterial activity against Gram-negative and Gram-positive bacteria, especially S. aureus, E. coli, K. pneumoniae and A. baumannii. Pharmaceutical compositions containing these compounds, therapeutic uses thereof and methods for manufacturing the same are also provided.

?-LACTAMASE INHIBITOR AND USE THEREOF

Provided are a β-lactamase inhibitor of formula (I), or an ester, a stereoisomer or a pharmaceutically acceptable salt thereof, and a method of preparing the same. Further provided is a pharmaceutical composition comprising the β-lactamase inhibitor of formula (I), or the ester, the stereoisomer or pharmaceutically acceptable salt thereof. In addition, the present invention relates to a method for treating diseases caused by bacterial infection, which comprises administering the β-lactamase inhibitor of formula (I), or the ester, the stereoisomer or the pharmaceutically acceptable salt thereof to a patient or a subject in need.

NON-FUSED TRICYCLIC COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES

The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.

GLYCOSAMINOGLYCAN DERIVATIVE AND METHOD FOR PRODUCING SAME

The present invention provides a glycosaminoglycan derivative in which a group derived from glycosaminoglycan and a group derived from a physiologically active substance having at least one of a carboxy group and a hydroxy group are coupled by covalent bond with a spacer therebetween, in which the spacer is selected in accordance with the decomposition rate of the covalent bond to the group derived from the physiologically active substance.

The discovery of potent, selective, and reversible inhibitors of the house dust mite peptidase allergen der p 1: An innovative approach to the treatment of allergic asthma

Blocking the bioactivity of allergens is conceptually attractive as a small-molecule therapy for allergic diseases but has not been attempted previously. Group 1 allergens of house dust mites (HDM) are meaningful targets in this quest because they are globally prevalent and clinically important triggers of allergic asthma. Group 1 HDM allergens are cysteine peptidases whose proteolytic activity triggers essential steps in the allergy cascade. Using the HDM allergen Der p 1 as an archetype for structure-based drug discovery, we have identified a series of novel, reversible inhibitors. Potency and selectivity were manipulated by optimizing drug interactions with enzyme binding pockets, while variation of terminal groups conferred the physicochemical and pharmacokinetic attributes required for inhaled delivery. Studies in animals challenged with the gamut of HDM allergens showed an attenuation of allergic responses by targeting just a single component, namely, Der p 1. Our findings suggest that these inhibitors may be used as novel therapies for allergic asthma.

NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS

Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.

CEPHEM COMPOUNDS

The present invention relates to a compound of the formula [I]: wherein R1 is lower alkyl, hydroxy(lower)alkyl or halo(lower)alkyl, and R2 is hydrogen or amino protecting group, or R1 and R2 are bonded together and form lower alkylene or lower alkenylene; R3 is hydrogen or lower alkyl; R4 is ; R5 is carboxy or protected carboxy; and R6 is amino or protected amino, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.

Design and synthesis of sulfur based inhibitors of matrix metalloproteinase-1.

Fibroblast collagenase (MMP-1), a member of the matrix metalloproteinases family, is believed to be a pathogenesis of arthritis, by cleaving triple-helical type II collagen in cartilage. From the similarity of the active site zinc binding mode with hydroxamate, we designed and synthesized alpha-mercaptocarbonyl possessing compounds (3-5), which incorporated various peptide sequences as enzyme recognition sites. The P4-P1 peptide incorporating compound (3) exhibited as potent inhibition as the hydroxamate (1) and the carboxylate (2) type inhibitors, with an IC50 of 10(-6) M order against MMP-1. But the inhibitor (3) related compounds (6-8) displayed decreased or no inhibitory potencies. These results suggest that the existence of both the carbonyl and thiol groups might be critical for the inhibition, and the distance between the two functional groups is important for inhibitory potency. For Pn' peptide incorporating compounds (4a-k), except for 4h and 4k, all compounds showed IC50 values under sub-nanomolar. Among them, for potent inhibition, Leu was better than Phe and Val as the P1' amino acid, and the P2' position amino acid was necessary, and preferentially Phe. Insertion of the Pn peptide into 4d or 4k, giving compounds 5a-c, did not increase the activities of 4d and 4k. Substitution of the mercapto group with other functional groups lost the activity of compound 4a. The stereochemical preference at the thiol-attached position was also determined by preparation of both isomers of 4a. It was found that the S configuration compound (36b) is approximately 100 times more potent than the corresponding R-isomer (36a).

Post a RFQ

Cas No.:

Product Name:

Quantity:

Please select Metric Ton KG G Pound L ML

Email:

Company name:

Valid Period:

Detailed Requirements:

• Sample
• MOQ
• GMP
• FDA
• Price
  FOB CIF CFR EXW
• Urgent purchase

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

Remove

Submit

1

What can I do for you?
Get Best Price

Get Best Price for 218916-64-4 Propanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy- (9CI)

Send

Send

Metric Ton KG G Pound L ML

Send

Send

Upstream product

• 632-12-2 (RS)-isoserine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 458531-74-3 {2-Hydroxy-2-[(S)-2-methyl-1-((S)-1-methylcarbamoyl-2-phenyl-ethylcarbamoyl)-propylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 458531-70-9 {2-Hydroxy-2-[(S)-1-((S)-2-methyl-1-methylcarbamoyl-propylcarbamoyl)-2-phenyl-ethylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 458531-72-1 {2-Hydroxy-2-[(S)-1-((S)-3-methyl-1-methylcarbamoyl-butylcarbamoyl)-2-phenyl-ethylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 458531-69-6 {2-Hydroxy-2-[(S)-3-methyl-1-((S)-1-methylcarbamoyl-2-phenyl-ethylcarbamoyl)-butylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 458531-66-3 (2-Hydroxy-2-{(S)-1-[(S)-2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethylcarbamoyl]-3-methyl-butylcarbamoyl}-ethyl)-carbamic acid tert-butyl ester 
• 458531-71-0 {2-Hydroxy-2-[(S)-1-((S)-1-methylcarbamoyl-2-phenyl-ethylcarbamoyl)-2-phenyl-ethylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 113525-87-4 methyl 3-((tert-butoxycarbonyl)amino)-2-hydroxypropanoate 
• 1350881-23-0 tert-butyl {2-(benzyloxy)-2-[3-(4-chlorophenyl)-1-(pyrimidin-2-yl)-1H-pyrazol-5-yl]ethyl}carbamate 
• 1350881-22-9 tert-butyl {2-(benzyloxy)-2-[3-(4-chloropheny)-1H-pyrazol-5-yl]ethyl}carbamate 
• 1350881-21-8 tert-butyl [2-(benzyloxy)-5-(4-chlorophenyI)-3-oxopent-4-yn-1-yl]carbamate 
• 1350881-20-7 tert-butyl {2-(benzyloxy)-3-[methoxy(methyl)amino]-3-oxopropyl}carbamate 
• 1020253-58-0 2-(benzyloxy)-3-[(tert-butoxycarbonyl)amino]propanoic acid 
• 1350881-19-4 benzyl 2-(benzyloxy)-3-[(tert-butoxycarbonyl)amino]propanoate 
• 252329-85-4 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(3-t-butoxycarbonylamino-2(R,S)-hydroxy-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AND THEIR USE

The present invention provides compounds of the general formula (I) or a pharmaceutically acceptable prodrugs, salts and/or solvates thereof, wherein LHS is selected from the group consisting of LHSa and LHSb And wherein, the asterisk (*) marks the point of attachment; These compounds exhibit antibacterial activity against Gram-negative and Gram-positive bacteria, especially S. aureus, E. coli, K. pneumoniae and A. baumannii. Pharmaceutical compositions containing these compounds, therapeutic uses thereof and methods for manufacturing the same are also provided.

?-LACTAMASE INHIBITOR AND USE THEREOF

Provided are a β-lactamase inhibitor of formula (I), or an ester, a stereoisomer or a pharmaceutically acceptable salt thereof, and a method of preparing the same. Further provided is a pharmaceutical composition comprising the β-lactamase inhibitor of formula (I), or the ester, the stereoisomer or pharmaceutically acceptable salt thereof. In addition, the present invention relates to a method for treating diseases caused by bacterial infection, which comprises administering the β-lactamase inhibitor of formula (I), or the ester, the stereoisomer or the pharmaceutically acceptable salt thereof to a patient or a subject in need.

NON-FUSED TRICYCLIC COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES

The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.

GLYCOSAMINOGLYCAN DERIVATIVE AND METHOD FOR PRODUCING SAME

The present invention provides a glycosaminoglycan derivative in which a group derived from glycosaminoglycan and a group derived from a physiologically active substance having at least one of a carboxy group and a hydroxy group are coupled by covalent bond with a spacer therebetween, in which the spacer is selected in accordance with the decomposition rate of the covalent bond to the group derived from the physiologically active substance.

The discovery of potent, selective, and reversible inhibitors of the house dust mite peptidase allergen der p 1: An innovative approach to the treatment of allergic asthma

Blocking the bioactivity of allergens is conceptually attractive as a small-molecule therapy for allergic diseases but has not been attempted previously. Group 1 allergens of house dust mites (HDM) are meaningful targets in this quest because they are globally prevalent and clinically important triggers of allergic asthma. Group 1 HDM allergens are cysteine peptidases whose proteolytic activity triggers essential steps in the allergy cascade. Using the HDM allergen Der p 1 as an archetype for structure-based drug discovery, we have identified a series of novel, reversible inhibitors. Potency and selectivity were manipulated by optimizing drug interactions with enzyme binding pockets, while variation of terminal groups conferred the physicochemical and pharmacokinetic attributes required for inhaled delivery. Studies in animals challenged with the gamut of HDM allergens showed an attenuation of allergic responses by targeting just a single component, namely, Der p 1. Our findings suggest that these inhibitors may be used as novel therapies for allergic asthma.

NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS

Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.

CEPHEM COMPOUNDS

The present invention relates to a compound of the formula [I]: wherein R1 is lower alkyl, hydroxy(lower)alkyl or halo(lower)alkyl, and R2 is hydrogen or amino protecting group, or R1 and R2 are bonded together and form lower alkylene or lower alkenylene; R3 is hydrogen or lower alkyl; R4 is ; R5 is carboxy or protected carboxy; and R6 is amino or protected amino, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.

Design and synthesis of sulfur based inhibitors of matrix metalloproteinase-1.

Fibroblast collagenase (MMP-1), a member of the matrix metalloproteinases family, is believed to be a pathogenesis of arthritis, by cleaving triple-helical type II collagen in cartilage. From the similarity of the active site zinc binding mode with hydroxamate, we designed and synthesized alpha-mercaptocarbonyl possessing compounds (3-5), which incorporated various peptide sequences as enzyme recognition sites. The P4-P1 peptide incorporating compound (3) exhibited as potent inhibition as the hydroxamate (1) and the carboxylate (2) type inhibitors, with an IC50 of 10(-6) M order against MMP-1. But the inhibitor (3) related compounds (6-8) displayed decreased or no inhibitory potencies. These results suggest that the existence of both the carbonyl and thiol groups might be critical for the inhibition, and the distance between the two functional groups is important for inhibitory potency. For Pn' peptide incorporating compounds (4a-k), except for 4h and 4k, all compounds showed IC50 values under sub-nanomolar. Among them, for potent inhibition, Leu was better than Phe and Val as the P1' amino acid, and the P2' position amino acid was necessary, and preferentially Phe. Insertion of the Pn peptide into 4d or 4k, giving compounds 5a-c, did not increase the activities of 4d and 4k. Substitution of the mercapto group with other functional groups lost the activity of compound 4a. The stereochemical preference at the thiol-attached position was also determined by preparation of both isomers of 4a. It was found that the S configuration compound (36b) is approximately 100 times more potent than the corresponding R-isomer (36a).